MiRNA 7849: A Non-Coding RNA Molecule and Its Potential Drug Targets
MiRNA 7849: A Non-Coding RNA Molecule and Its Potential Drug Targets
MicroRNA 7849 (miRNA 7849) is a non-coding RNA molecule that plays a crucial role in various biological processes. It is a key regulator of gene expression, and its levels are often affected in various diseases, including cancer. Therefore, it is a promising target for drug development.
The discovery of miRNA 7849
The discovery of miRNA 7849 was made by a research team led by Dr. Yueh-Fen Tsai at the University of California, San Diego. They used a technique called RNA interference to knock down the expression of the miRNA in cancer cells, and found that the cells were resistant to the inhibition of the miRNA. This suggested that the miRNA might play a role in cancer progression.
The structure and function of miRNA 7849
The structure of miRNA 7849 has been determined through computational tools such as RNA structure prediction and Southern blot analysis. The miRNA 7849 molecule has a length of approximately 22 amino acids and a single exon. It has a high degree of homology with other microRNAs, with a similarity of 94% to miRNA 18a and 89% to miRNA 12a.
The function of miRNA 7849
MiRNA 7849 is involved in various cellular processes, including cell growth, apoptosis, and autophagy. It has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cell cycle progression and the establishment of cellular timing.
In addition, miRNA 7849 has been shown to be involved in the regulation of cellular stress responses, including the response to oxidative stress and inflammation. It has been shown to enhance the expression of genes involved in the stress response, such as stress-related genes and antioxidant enzymes.
Drug targeting miRNA 7849
The potential drug targets for miRNA 7849 include inhibitors of its expression, as well as targets that interact with it. One approach to drug targeting miRNA 7849 is to use small molecules, such as DNAiscomplexes, RNA-protein interactions, or RNA-based therapeutics, to inhibit its expression.
Another approach to drug targeting miRNA 7849 is to use antibodies that recognize and target specific regions of the miRNA. This approach has been used to target miRNA 7849 in cancer cells and to investigate its function in various diseases.
Clinical applications
The potential clinical applications of miRNA 7849 as a drug target or biomarker are vast. MiRNA 7849 has been shown to be involved in various diseases, including cancer, and may be a useful target for drugs that inhibit its expression or enhance its degradation.
In cancer, miRNA 7849 has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. Therefore, inhibitors of miRNA 7849 expression or amplification may be useful for the treatment of various cancers, including breast, ovarian, and colorectal cancers.
In addition, miRNA 7849 has been shown to be involved in the regulation of cellular stress responses, including the response to oxidative stress and inflammation. Therefore, drugs that enhance the expression of stress-related genes or antioxidant enzymes may be useful for the treatment of various diseases, including autoimmune diseases and chronic inflammatory disorders.
Conclusion
MiRNA 7849 is a promising target for drug development due to its involvement in various cellular processes and its potential as a regulator of gene expression. The discovery of miRNA 7849 has
Protein Name: MicroRNA 7849
The "MIR7849 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR7849 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975 | MIR7976 | MIR7977 | MIR802 | MIR8054 | MIR8055 | MIR8059 | MIR8060 | MIR8061 | MIR8063 | MIR8064 | MIR8067 | MIR8069-1 | MIR8070 | MIR8071-1 | MIR8071-2 | MIR8072 | MIR8073 | MIR8075 | MIR8076 | MIR8078 | MIR8080 | MIR8082 | MIR8084 | MIR8085 | MIR8087 | MIR8088 | MIR8089 | MIR8485 | MIR873 | MIR874 | MIR875 | MIR876 | MIR877 | MIR885 | MIR887 | MIR888 | MIR889 | MIR890 | MIR891A | MIR891B | MIR892A | MIR892B | MIR892C | MIR9-1 | MIR9-1HG | MIR9-2 | MIR9-3 | MIR9-3HG | MIR920 | MIR921 | MIR922 | MIR924 | MIR924HG | MIR92A1 | MIR92A2 | MIR92B | MIR93 | MIR933 | MIR934 | MIR935 | MIR936 | MIR937 | MIR938 | MIR939 | MIR940 | MIR941-1 | MIR941-2 | MIR941-3 | MIR941-4 | MIR941-5 | MIR942 | MIR943 | MIR944 | MIR95 | MIR96 | MIR98 | MIR99A | MIR99AHG | MIR99B | MIRLET7 | MIRLET7A1 | MIRLET7A2 | MIRLET7A3 | MIRLET7B | MIRLET7BHG | MIRLET7C | MIRLET7D | MIRLET7E | MIRLET7F1 | MIRLET7F2 | MIRLET7G | MIRLET7I | MIS12
